Annual report pursuant to Section 13 and 15(d)

ACQUISITIONS - Acquisition of Beacon Bio and Business Combination (Details)

v3.24.0.1
ACQUISITIONS - Acquisition of Beacon Bio and Business Combination (Details)
 1 Months Ended 12 Months Ended
Jun. 10, 2021
USD ($)
shares
Dec. 09, 2020
USD ($)
$ / shares
shares
Dec. 31, 2020
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2023
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Business Acquisition            
Common stock, shares authorized         500,000,000 500,000,000
Common stock par value (in dollars per share) | $ / shares         $ 0.0001 $ 0.0001
Preferred stock, shares authorized         50,000,000 50,000,000
Preferred stock par value (in dollars per share) | $ / shares         $ 0.0001 $ 0.0001
2021 Acquisitions            
Business Acquisition            
Additional payment | $ $ 1,000,000.0          
Beacon Bio            
Business Acquisition            
Cash consideration | $ 6,100,000          
Transaction costs | $ $ 200,000          
Asset acquisition, equity interest issued, number of shares 334,370          
Vesting period 3 years          
Trine            
Business Acquisition            
Exchange ratio   1.22122        
Shares authorized   550,000,000        
Common stock, shares authorized   500,000,000        
Common stock par value (in dollars per share) | $ / shares   $ 0.0001        
Preferred stock, shares authorized   50,000,000        
Preferred stock par value (in dollars per share) | $ / shares   $ 0.0001        
Shares issued in PIPE financing     27,497,500      
Price per share | $ / shares   $ 12.50        
Cash - PIPE financing | $       $ 274,975,000    
Trine | Business Combination Subscription Agreement            
Business Acquisition            
Shares issued in PIPE financing   27,497,500        
Price per share | $ / shares   $ 10.00        
Cash - PIPE financing | $   $ 275,000,000        
Common Stock | Beacon Bio            
Business Acquisition            
Purchase consideration related to value of shares | $ $ 4,300,000